Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 11;24(14):11328.
doi: 10.3390/ijms241411328.

Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria

Nadja Højgaard Pedersen  1 , Jennifer Astrup Sørensen  1 , Misbah Noshela Ghazanfar  1 , Ditte Georgina Zhang  1 , Christian Vestergaard  2 , Simon Francis Thomsen  1   3
Affiliations
Review

Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria

Nadja Højgaard Pedersen et al. Int J Mol Sci. .

Abstract

Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and these are also being investigated as potential biomarkers in the diagnosis and management of the disease. As of now the only assessment tools available for treatment response are patient reported outcomes (PROs). Although these tools are both validated and widely used, they leave a desire for more objective measurements. A biomarker is a broad subcategory of observations that can be used as an accurate, reproducible, and objective indicator of clinically relevant outcomes. This could be normal biological or pathogenic processes, or a response to an intervention or exposure, e.g., treatment response. Herein we provide an overview of biomarkers for CU, with a focus on prognostic biomarkers for treatment response to omalizumab, thereby potentially aiding physicians in personalizing treatments.

Keywords: anti-IgE; biomarkers; chronic spontaneous urticaria; chronic urticaria; omalizumab; treatment response.

PubMed Disclaimer

Conflict of interest statement

N.H.P has not conflicts of interest to declare. J.A.S. has no conflicts of interest to declare. M.N.G. has no conflicts of interest to declare. D.G.Z. has no conflicts of interest to declare. C.V. has recived honoraria/unrestricted garnt/acted on addboards for Novartis, Sanofi-Genzyme, Abbvie, Pfizer, LEO Pharma, Almirall, OM-Pharma, Pierre Fabre, and Astra Zeneca, Eli Lilly. S.F.T. has been a speaker or has served on advisory boards for Sanofi-Genzyme, AbbVie, LEO Pharma, Pfizer, Eli Lilly and Company, Novartis, UCB Pharma, Almirall, and Janssen Pharmaceuticals; has received research support from Sanofi-Genzyme, AbbVie, LEO Pharma, Novartis, UCB Pharma, and Janssen Pharmaceuticals; and has been an investigator for Sanofi-Genzyme, Regeneron, AbbVie, LEO Pharma, and Pfizer.

References

    1. Zuberbier T., Abdul Latiff A.H., Abuzakouk M., Aquilina S., Asero R., Baker D., Ballmer-Weber B., Bangert C., Ben-Shoshan M., Bernstein J.A., et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy Eur. J. Allergy Clin. Immunol. 2022;77:734–766. doi: 10.1111/all.15090. - DOI - PubMed
    1. Ghazanfar M.N., Kibsgaard L., Thomsen S.F., Vestergaard C. Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study. World Allergy Organ. J. 2020;13:100097. doi: 10.1016/j.waojou.2019.100097. - DOI - PMC - PubMed
    1. Godse K., Mehta A., Patil S., Gautam M., Nadkarni N. Omalizumab—A Review. Indian J Dermatol. 2015;60:381. doi: 10.4103/0019-5154.160490. - DOI - PMC - PubMed
    1. Mendes-Bastos P., Brasileiro A., Kolkhir P., Frischbutter S., Scheffel J., Moñino-Romero S., Maurer M. Bruton’s tyrosine kinase inhibition—An emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy Eur. J. Allergy Clin. Immunol. 2022;77:2355–2366. doi: 10.1111/all.15261. - DOI - PMC - PubMed
    1. Terhorst-Molawi D., Hawro T., Grekowitz E., Kiefer L., Merchant K., Alvarado D., Thomas L.J., Hawthorne T., Crowley E., Heath-Chiozzi M., et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78:1269–1279. doi: 10.1111/all.15585. - DOI - PubMed